GHK-Cu
Injectable GHK-Cu is tracked separately from topical cosmetic use because the injectable form sits in a much riskier regulatory bucket.
Current status
Restricted
Skin rejuvenation and wound repair, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Injectable formulations draw most of the regulatory concern and are the ones to watch for future status changes.
Primary Use
Skin rejuvenation and wound repair
Regulatory Timeline
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Sep 29, 2023
Current status signal recorded: Injectable use remains in the restricted compounding group..
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Get notified...
Get notified when GHK-Cu status changes
State-specific notes
Ohio
Sterile compounding caution is elevated.
California
Compounding access is highly limited.